Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Influence of Timing of Cabergoline Initiation on Prevention of Ovarian Hyper Stimulation Syndrome in Patients Undergoing Intra Cytoplasmic Sperm Injection .

Next Previous
Trial Profile

The Influence of Timing of Cabergoline Initiation on Prevention of Ovarian Hyper Stimulation Syndrome in Patients Undergoing Intra Cytoplasmic Sperm Injection .

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabergoline (Primary)
  • Indications Ovarian hyperstimulation syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 08 Apr 2018 Planned End Date changed from 1 Jun 2017 to 1 Apr 2019.
  • 08 Apr 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2018.
  • 21 Feb 2017 Planned End Date changed from 1 Jul 2016 to 1 Jun 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top